David Colville

Dr. David Colville serves as Professor of Nuclear Medicine and Clinical Molecular Imaging at the University of Glasgow with a clinical research focus at Gartnavel General Hospital. His work integrates advanced molecular imaging techniques to address critical challenges in cardiovascular disease and oncology, maintaining an active research profile evidenced by 2025 publications in high-impact journals.

His research program centers on nuclear medicine applications with dual emphases: cardiovascular imaging (atherosclerosis quantification, anthracycline-induced vascular damage) and oncological imaging (tumor glucose metabolism, bone metastasis detection, cancer-inflammation interactions). He pioneers the use of [18F]FDG PET/CT and digital PET technology for high-resolution inflammatory and structural assessments, bridging preclinical models with clinical patient studies.

Recent publications (2024-2025) demonstrate a clear trajectory toward translational cardiovascular-oncology, particularly investigating anthracycline cardiotoxicity mechanisms using non-human primate models and lymphoma patients. His work consistently leverages quantitative imaging biomarkers to link molecular processes with clinical outcomes, with earlier research establishing foundational insights into tumor metabolism-inflammation crosstalk. The 2010-2019 publications reveal progressive methodological refinement from SPECT/CT bone scan validation to sophisticated digital PET analytics.

No scientific awards were documented in available materials. Information regarding graduate student supervision, grant funding portfolios, laboratory infrastructure, or collaborative research teams was absent from the source text, though his multi-institutional publications indicate active clinical research partnerships.